Crawley J N
Clinical Neuroscience Branch, National Institute of Mental Health, Bethesda, MD 20892.
Brain Res. 1988 Nov 15;473(2):398-400. doi: 10.1016/0006-8993(88)90874-8.
A dark-induced hyperlocomotion paradigm was developed to investigate the role of endogenous cholecystokinin in mediating exploratory locomotor activity in the mesolimbic pathway, where cholecystokinin coexists with dopamine. Microinjection of the cholecystokinin receptor antagonist, proglumide, 10-20 micrograms, into the medial posterior nucleus accumbens, significantly inhibited dark-induced hyperlocomotion, while having no effect on locomotion in the light. These data suggest that endogenous cholecystokinin contributes to behaviorally relevant functions of the activated mesolimbic pathway.
为了研究内源性胆囊收缩素在介导中脑边缘通路探索性运动活动中的作用，开发了一种黑暗诱导的运动亢进范式，在该通路中胆囊收缩素与多巴胺共存。向伏隔核内侧后核微量注射10 - 20微克胆囊收缩素受体拮抗剂丙谷胺，可显著抑制黑暗诱导的运动亢进，而对光照下的运动没有影响。这些数据表明内源性胆囊收缩素有助于激活的中脑边缘通路的行为相关功能。
